Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Illinois at Chicago
Study ID
NCT07175051
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Albuminuria
  • Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Sickle cell anemia (SCA) is an inherited red blood disorder. The kidneys are among the most commonly affected organ systems in SCA. The Food and Drug Administration (FDA) has approved empagliflozin as a treatment to reduce the decline of kidney function in those with kidney disease. The proposed research study aims to determine whether empagliflozin can prevent the progression of kidney dysfunction in patients with sickle cell anemia (SCA) who are at high risk of developing advanced chronic kidney disease (CKD).

Key Dates

Start date
Apr 8, 2026
Status verified
May 2026
Primary completion
Oct 31, 2029
Completion
Oct 31, 2030

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    Empagliflozin

Primary Outcome Measure

Efficacy of empagliflozin - urine biomarker: Adenosine [ Time Frame: From enrollment to the end of treatment at 48 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Illinois Chicago, Sickle Cell CenterChicagoIllinois60302
Santosh L Saraf, MD
[email protected]
312-996-5680
Anand Srivastava, MD

Find similar trials in Chicago, IL

By research site
University of Illinois Chicago, Sickle Cell Center· Chicago, IL

Related Studies